24th November 2009

PRESS RELEASE

UNIVERSITY OF SYDNEY STUDY FINDS IMPEDIMED’S BIS DEVICE THE MOST SUITABLE MEASUREMENT FOR EARLY DETECTION AND MONITORING OF LYMPHOEDEMA

A study conducted by researchers from the University of Sydney’s Breast Cancer Research Group and published this month in the journal *Cancer Investigation*, has established that ‘as BIS is the only measurement method specific to extracellular fluid, it is ideally suited for early detection and monitoring of lymphedema’ [1].

The study was a comparison of physical measurement methods and self report in the assessment of breast cancer-related arm lymphoedema. It observed that the results from physical measurement methods other than BIS may be confounded by changes not related to lymphoedema such as muscle and fat. Therefore, early lymphoedema build up may go undetected when using these measurement methods.

ImpediMed CEO Greg Brown said, ‘This latest study adds weight to the debate presently being held around the globe about the need for standardised objective metrics driving evidence based medicine. ImpediMed is very focussed on changing the care model for lymphoedema management in cancer patients from a reactive to a prospective one. If lymphoedema can be detected early, progression to the irreversible stages of the condition may be prevented, affording the patient a far better quality of life. We are pleased to be able to offer our L-Dex® U400 device to clinicians to aid them in the early clinical assessment of lymphoedema. '


For further information contact:

Greg Brown ImpediMed CEO +61-7-3860-3700
L-Dex® is a trademark of ImpediMed Limited.

* L-Dex® values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity*.

**About ImpediMed**

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit [www.impedimed.com](http://www.impedimed.com).